Clinical Trial Update: Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of dasatinib in combination with melphalan and prednisone for relapsed or refractory multiple myeloma, which …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alkeran (melphalan)
• PREDNISONE (Prednisone)
• Sprycel (dasatinib)

Snippet

Sponsor: Fondazione EMN Italy Onlus | Conditions: Myeloma | Phase 2 | Status: TERMINATED